NEREUS Launch Marks Major Breakthrough for Motion Sickness—First New Prescription Option in Over 40 Years

NEREUS Emerges as a Game-Changer for Millions Facing Motion Sickness

For the estimated 65 to 78 million Americans affected by motion sickness, treatment options have barely changed for decades. That changes with today’s announcement from Vanda Pharmaceuticals: NEREUS™ (tradipitant) is now available across the United States, marking the first new prescription therapy for motion sickness approved in over 40 years. With NEREUS, Vanda brings a new approach—based on targeting neurokinin-1 (NK-1) receptors—giving hope to everyone from daily commuters to frequent flyers and sailors.

Why NEREUS Stands Out: Efficacy, Mechanism, and Access

Unlike older treatments, NEREUS™ blocks substance P/NK-1 receptors believed to drive the vomiting center in the brain, tackling the root cause of motion-induced nausea rather than just masking symptoms. It is the result of two pivotal Phase 3 clinical trials, Motion Syros and Motion Serifos, both conducted on the open sea, demonstrating that NEREUS significantly reduced vomiting compared to placebo under real travel conditions. For the first time, patients can access this medicine via a dedicated direct-to-consumer portal at nereus.us, with a cash-pay price of $85 per dose—a notable discount from the standard list price of $255.

Direct-to-Consumer Platform Offers Unprecedented Convenience

NEREUS is available both through traditional retail pharmacy channels and via an online portal—making it especially convenient for busy travelers. Patients with a valid prescription can order NEREUS for home delivery, putting the treatment just a click away for anyone facing a last-minute trip or regular travel demands.

Clinical Trial Success Under Real-World Conditions

What sets NEREUS apart isn’t just that it’s new—it’s that it has been tested where motion sickness happens most: out at sea. The Phase 3 trials demonstrated robust efficacy in preventing vomiting among travelers exposed to genuine motion environments, not only reinforcing the drug’s value but also validating the underlying receptor-targeting science behind its design.

Safety and Patient Considerations Remain Front and Center

Common side effects for NEREUS include drowsiness, headache, and fatigue. Importantly, it may impair activities requiring alertness, such as driving. Patients with liver problems, severe kidney issues, or those combined with certain sedatives, should work closely with healthcare providers to assess suitability. Pregnant or breastfeeding patients should discuss risks, as data remains limited. Safety and effectiveness have not been established for pediatric use.

Looking Ahead: What This Means for Vanda and the Broader Market

NEREUS not only fills a long-standing treatment gap but positions Vanda Pharmaceuticals as a major innovator in addressing high-prevalence conditions with unmet needs. The drug is also being investigated for other potential indications, such as gastroparesis and nausea induced by GLP-1 receptor agonists, suggesting further growth avenues.

Key Takeaways for Investors and Consumers

The launch of NEREUS could redefine the market for motion sickness therapies. With its modern mechanism, real-world efficacy, and vastly improved access model, NEREUS sets a new standard for the category. For investors, Vanda’s ability to deliver innovative, differentiated products could translate into sustainable long-term value—pending real uptake and competitive dynamics in this newly revived space.

Additional Resources

To order NEREUS or for full prescribing information, visit nereus.us. For more details on Vanda Pharmaceuticals, visit vandapharma.com.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI